Compare Stocks

→ Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$7.26 +0.8%	$9.28	$2.09 ▼ $14.84	$514.66M	0.05	5.32 million shs	2.25 million shs
CALA Calithera Biosciences	$0.02	$0.02	$0.01 ▼ $0.50	$97K	-0.17	1,535 shs	261 shs
CNCE Concert Pharmaceuticals	$8.37	$8.37	$2.66 ▼ $8.55	$401.26M	0.52	2.97 million shs	N/A
KALV KalVista Pharmaceuticals	$10.78 +2.8%	$12.36	$7.21 ▼ $16.88	$454.81M	0.88	719,135 shs	241,417 shs
XOMA XOMA	$25.41 +0.2%	$24.86	$13.48 ▼ $27.00	$295.77M	0.58	20,669 shs	6,127 shs

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	+1.69%	+4.50%	-16.76%	-22.83%	+37.93%
CALA Calithera Biosciences	-31.03%	-20.16%	0.00%	-33.33%	-52.61%
CNCE Concert Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
KALV KalVista Pharmaceuticals	+1.35%	-8.78%	-5.58%	-21.54%	+31.13%
XOMA XOMA	-1.09%	+3.13%	+9.55%	+25.61%	+32.08%

Protect Yourself While There’s Still Time … (Ad)

The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.

4 simple steps to protect your privacy and money before it’s too late.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALT Altimmune	1.3614 of 5 stars	3.3	1.0	0.0	0.0	3.1	1.7	0.0
CALA Calithera Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CNCE Concert Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	4.0246 of 5 stars	3.5	1.0	0.0	4.6	2.6	2.5	0.6
XOMA XOMA	3.5097 of 5 stars	3.5	1.0	0.0	3.0	2.5	1.7	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALT Altimmune	2.67	Moderate Buy	$15.00	106.61% Upside
CALA Calithera Biosciences	N/A	N/A	N/A	N/A
CNCE Concert Pharmaceuticals	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	3.00	Buy	$26.33	144.28% Upside
XOMA XOMA	3.00	Buy	$74.00	191.22% Upside

Current Analyst Ratings

Latest CNCE, KALV, ALT, CALA, and XOMA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/25/2024	XOMA XOMA	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$74.00
4/11/2024	KALV KalVista Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
4/1/2024	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00
3/28/2024	ALT Altimmune	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
2/16/2024	XOMA XOMA	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$74.00
2/14/2024	KALV KalVista Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$16.00 ➝ $24.00
2/13/2024	ALT Altimmune	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
2/13/2024	KALV KalVista Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$22.00 ➝ $35.00

(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALT Altimmune	$430K	1,196.89	N/A	N/A	$2.75 per share	2.64
CALA Calithera Biosciences	$9.75M	0.01	N/A	N/A	($0.40) per share	-0.05
CNCE Concert Pharmaceuticals	$32.58M	12.32	N/A	N/A	$3.24 per share	2.58
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	$4.71 per share	N/A
XOMA XOMA	$4.76M	62.14	N/A	N/A	$7.72 per share	3.29

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALT Altimmune	-$88.45M	-$1.65	N/A	N/A	N/A	-20,780.75%	-44.77%	-40.72%	5/9/2024 (Estimated)
CALA Calithera Biosciences	-$39.65M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CNCE Concert Pharmaceuticals	-$80.05M	-$3.21	N/A	N/A	N/A	N/A	-109.43%	-76.65%	N/A
KALV KalVista Pharmaceuticals	-$92.91M	-$3.15	N/A	N/A	N/A	N/A	-86.06%	-72.65%	7/5/2024 (Estimated)
XOMA XOMA	-$40.83M	-$4.04	N/A	N/A	N/A	-886.91%	-25.17%	-17.08%	5/14/2024 (Estimated)

Latest CNCE, KALV, ALT, CALA, and XOMA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/27/2024	Q4 2023	ALT Altimmune	-$0.35	-$0.33	+$0.02	-$0.12	N/A	$0.04 million
3/11/2024	Q3 2024	KALV KalVista Pharmaceuticals	-$0.75	-$0.84	-$0.09	-$0.84	N/A	N/A
3/8/2024	Q4 2023	XOMA XOMA	-$0.36	-$0.49	-$0.13	$0.89	$1.01 million	$1.83 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALT Altimmune	N/A	N/A	N/A	N/A	N/A
CALA Calithera Biosciences	N/A	N/A	N/A	N/A	N/A
CNCE Concert Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
XOMA XOMA	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALT Altimmune	N/A	17.26	17.26
CALA Calithera Biosciences	N/A	N/A	N/A
CNCE Concert Pharmaceuticals	N/A	9.03	9.03
KALV KalVista Pharmaceuticals	N/A	5.44	5.44
XOMA XOMA	1.34	8.68	8.68

Ownership

Institutional Ownership

Company	Institutional Ownership
ALT Altimmune	78.05%
CALA Calithera Biosciences	N/A
CNCE Concert Pharmaceuticals	70.63%
KALV KalVista Pharmaceuticals	N/A
XOMA XOMA	95.92%

Insider Ownership

Company	Insider Ownership
ALT Altimmune	4.10%
CALA Calithera Biosciences	6.60%
CNCE Concert Pharmaceuticals	11.33%
KALV KalVista Pharmaceuticals	12.30%
XOMA XOMA	7.20%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ALT Altimmune	59	70.89 million	67.99 million	Optionable
CALA Calithera Biosciences	8	4.87 million	4.55 million	Not Optionable
CNCE Concert Pharmaceuticals	64	47.94 million	42.51 million	Optionable
KALV KalVista Pharmaceuticals	118	42.19 million	37.00 million	Optionable
XOMA XOMA	13	11.64 million	10.80 million	Optionable

CNCE, KALV, ALT, CALA, and XOMA Headlines

Source	Headline
$XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)$	XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) finance.yahoo.com - April 25 at 8:40 AM
	XOMA's (XOMA) Buy Rating Reiterated at HC Wainwright marketbeat.com - April 25 at 8:09 AM
$XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day Ones OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)$	XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) globenewswire.com - April 25 at 7:30 AM
	XOMA (NASDAQ:XOMA) Share Price Crosses Above 200-Day Moving Average of $20.30 americanbankingnews.com - April 25 at 3:14 AM
	Actym Therapeutics Appoints Thomas Smart as CEO prnewswire.com - April 24 at 9:00 AM
	XOMA (NASDAQ:XOMA) shareholders have earned a 16% CAGR over the last five years finance.yahoo.com - April 20 at 9:43 AM
	XOMA (NASDAQ:XOMA) Share Price Passes Above Two Hundred Day Moving Average of $19.93 americanbankingnews.com - April 17 at 2:58 AM
	XOMA Co. (NASDAQ:XOMA) Shares Sold by Stonepine Capital Management LLC marketbeat.com - April 9 at 9:43 PM
	XOMA Corporation Announces Closing of Tender Offer globenewswire.com - April 3 at 9:00 AM
	XOMA Declares Quarterly Preferred Stock Dividends globenewswire.com - March 21 at 7:30 AM
	XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc. globenewswire.com - March 19 at 4:05 PM
	KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE businesswire.com - March 13 at 11:49 AM
	XOMA Stock Earnings: XOMA Misses EPS, Misses Revenue for Q4 2023 investorplace.com - March 8 at 1:03 PM
	XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value finance.yahoo.com - March 8 at 7:51 AM
	XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value globenewswire.com - March 8 at 7:30 AM
	XOMA to Present at Upcoming Investor Conferences in March globenewswire.com - February 28 at 7:30 AM
	KINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE businesswire.com - February 19 at 11:03 AM
	Compare with Maple Leaf Green World Inc (4HV0) msn.com - February 18 at 12:30 PM
	XOMA to acquire Kinnate Biopharma thepharmaletter.com - February 17 at 10:21 AM
	XOMA Mar 2024 20.000 put finance.yahoo.com - February 17 at 10:21 AM
	XOMA Jun 2024 25.000 call finance.yahoo.com - February 17 at 10:21 AM
	Biotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharma benzinga.com - February 16 at 1:37 PM
	XOMA Agrees to Acquire Kinnate Biopharma marketwatch.com - February 16 at 8:36 AM
	XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right finance.yahoo.com - February 16 at 8:36 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
April 24, 2024 10:40 AM
View Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
3M Spun Off Its Health Division, Is It Still A Buy?
April 4, 2024 7:47 AM
View 3M Spun Off Its Health Division, Is It Still A Buy?
4 Dividend Aristocrats Trading at a Discount
April 1, 2024 6:10 AM
View 4 Dividend Aristocrats Trading at a Discount
Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?
April 9, 2024 6:07 AM
View Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?
Undervalued UnitedHealth Group Won’t Be For Long
April 16, 2024 10:53 AM
View Undervalued UnitedHealth Group Won’t Be For Long

All Headlines

Company Descriptions

Altimmune

NASDAQ:ALT

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Calithera Biosciences

NASDAQ:CALA

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Concert Pharmaceuticals

NASDAQ:CNCE

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

KalVista Pharmaceuticals

NASDAQ:KALV

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

XOMA

NASDAQ:XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial